|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.44 USD | -0.95% |
|
-3.78% | -27.96% |
| 08-19 | Cidara Therapeutics Names Jim Beitel as Chief Business Officer | MT |
| 08-19 | Cidara Therapeutics Appoints Jim Beitel as Chief Business Officer | CI |
| Capitalization | 80.52M 6.13B | P/E ratio 2024 * |
-0.44x | P/E ratio 2025 * | -1.15x |
|---|---|---|---|---|---|
| Enterprise value | 80.52M 6.13B | EV / Sales 2024 * |
11.4x | EV / Sales 2025 * | - |
| Free-Float |
95.24% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Cidara Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | -0.95% | ||
| 1 week | -3.78% | ||
| Current month | -3.78% | ||
| 1 month | +1.33% | ||
| 3 months | -10.90% | ||
| 6 months | -16.25% | ||
| Current year | -27.96% |
1 week
10.76
11.99
1 month
10.7613.36
Current year
10.0024.40
1 year
10.0024.40
3 years
8.0047.80
5 years
8.0089.00
10 years
8.00382.60
| Director | Title | Age | Since |
|---|---|---|---|
Jeffrey Stein
CEO | Chief Executive Officer | 69 | 31/12/13 |
Preetam Shah
DFI | Director of Finance/CFO | 51 | 31/08/21 |
Shane Ward
COO | Chief Operating Officer | 49 | 31/08/21 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jeffrey Stein
CEO | Chief Executive Officer | 69 | 31/12/13 |
| Director/Board Member | 69 | 31/03/14 | |
Daniel Burgess
CHM | Chairman | 62 | 31/03/14 |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.95% | -3.78% | -42.02% | -72.37% | 80.52M | ||
| -1.66% | -4.49% | +37.11% | +69.18% | 122B | ||
| -0.12% | -5.62% | +36.06% | +143.50% | 121B | ||
| +0.27% | +4.17% | +1.75% | +67.91% | 32.37B | ||
| -0.23% | +1.95% | -24.88% | -74.05% | 21.38B | ||
| -0.14% | -0.24% | -1.51% | -44.80% | 20.33B | ||
| -0.27% | -0.72% | -29.20% | -37.25% | 17.58B | ||
| -2.17% | -0.97% | -49.15% | -72.52% | 15.54B | ||
| -0.46% | +38.16% | +123.97% | +330.81% | 12.45B | ||
| -3.63% | -5.05% | +5.67% | +64.08% | 12.29B | ||
| Average | -0.94% | +2.72% | +5.78% | +37.45% | 37.49B | |
| Weighted average by Cap. | -0.81% | -1.63% | +23.24% | +76.29% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 7.09M 540M | - |
| Net income | -168M -12.8B | -119M -9.05B |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
69
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/09/24 | 11.44 $ | -0.95% | 4,341 |
| 05/09/24 | 11.55 $ | +2.08% | 4,227 |
| 04/09/24 | 11.32 $ | -2.37% | 42,580 |
| 03/09/24 | 11.59 $ | -2.52% | 10,369 |
| 30/08/24 | 11.89 $ | -8.19% | 40,636 |
Delayed Quote Nasdaq, September 06, 2024 at 09:00 pm
More quotesSell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
11.44USD
Average target price
24.50USD
Spread / Average Target
+114.16%
- Stock Market
- Equities
- CDTX Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition